Tonix Pharmaceuticals to Host Live Webinar: Antibody vs. T Cell Immunity: Is a Single Vaccine Enough to Stop COVID-19?
September 17 2020 - 9:17AM
Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the
Company), a clinical-stage biopharmaceutical company, today
announced that it will host a live webinar on Thursday, September
24, 2020 at 10:00 a.m. ET to discuss the concept of two types of
immune responses – antibody vs. T Cell – as well as provide an
overview of the challenges of developing an effective vaccine.
Participating panelists for the event will be:
- Swati Gupta, Vice President and Head of
Emerging Infectious Diseases and Scientific Strategy, IAVI. Click
HERE for full bio.
- Seth Lederman, M.D., Co-Founder and CEO, Tonix
Pharmaceuticals. Click HERE for full bio.
- Gokul Swaminathan, Associate Principal
Scientist, Investigational Biology, Merck Research Laboratories.
Click HERE for full bio.
The webinar will be held virtually and will include a Q&A
session moderated by Clive Cookson, renowned
Science Editor of The Financial Times. Click HERE to register
and access the Zoom link for this event.
Details are as follows:
Event: |
Antibody vs. T Cell Immunity: Is a Single Vaccine Enough to Stop
COVID-19? |
Format: |
Virtual webinar followed by moderated Q&A session |
Date |
Thursday, September 24, 2020 |
Time |
10:00 a.m. – 11:30 a.m. ET |
A subsequent archived recording of the webinar and Q&A
session will be available under the IR Events tab of the Investors
section of the Tonix website at www.tonixpharma.com.
About Tonix Pharmaceuticals Holding Corp.Tonix
is a clinical-stage biopharmaceutical company focused on
discovering, licensing, acquiring and developing small molecules
and biologics to treat and prevent human disease and alleviate
suffering. Tonix’s portfolio is primarily composed of central
nervous system (CNS) and immunology product candidates. The
immunology portfolio includes vaccines to prevent infectious
diseases and biologics to address immunosuppression, cancer and
autoimmune diseases. The CNS portfolio includes both small
molecules and biologics to treat pain, neurologic, psychiatric and
addiction conditions. Tonix’s lead vaccine candidate, TNX-1800*, is
a live replicating, attenuated vaccine based on the horsepox viral
vector platform to protect against COVID-19, primarily by eliciting
a T cell response. Tonix expects data from animal studies of
TNX-1800 in the fourth quarter of this year. TNX-801*, live
horsepox virus vaccine for percutaneous administration, is in
development to protect against smallpox and monkeypox and serves as
the vector platform on which TNX-1800 is based. Tonix is also
developing TNX-2300* and TNX-2600*, live replicating vaccine
candidates for the prevention of COVID-19, but using bovine
parainfluenza as the vector. Tonix’s lead CNS candidate, TNX-102
SL**, is in Phase 3 development for the management of fibromyalgia.
The Company expects results from an unblinded interim analysis in
September 2020 and topline data in the fourth quarter of
2020. Tonix is also currently enrolling patients in a second
Phase 3 study for the management of fibromyalgia using TNX-102 SL,
the results for which are expected in the second half of 2021.
TNX-102 SL is also in development for agitation in Alzheimer’s
disease and alcohol use disorder (AUD). The agitation in
Alzheimer’s disease program is Phase 2 ready with FDA Fast Track
designation, and the AUD program is also Phase 2 ready. Tonix‘s
programs for treating addiction conditions also include TNX-1300*
(T172R/G173Q double-mutant cocaine esterase 200 mg, i.v. solution),
which is in Phase 2 development for the treatment of
life-threatening cocaine intoxication and has FDA Breakthrough
Therapy designation. TNX-601 CR** (tianeptine oxalate
controlled-release tablets) is another CNS program, currently in
Phase 1 development as a daytime treatment for depression while
TNX-1900**, intranasal oxytocin, is in development as a
non-addictive treatment for migraine and cranio-facial pain.
Tonix’s preclinical pipeline includes TNX-1600** (triple reuptake
inhibitor), a new molecular entity being developed as a treatment
for PTSD; TNX-1500* (anti-CD154), a monoclonal antibody being
developed to prevent and treat organ transplant rejection and
autoimmune conditions; and TNX-1700* (rTFF2), a biologic being
developed to treat gastric and pancreatic cancers.
*TNX-1800, TNX-801, TNX-2300, TNX-2600, TNX-1300, TNX-1500 and
TNX-1700 are investigational new biologics and have not been
approved for any indication.
**TNX-102 SL, TNX-601 CR, TNX-1600 and TNX-1900 are
investigational new drugs and have not been approved for any
indication.
This press release and further information about Tonix can be
found at www.tonixpharma.com.
Forward-Looking Statements
Certain statements in this press release are forward-looking
within the meaning of the Private Securities Litigation Reform Act
of 1995. These statements may be identified by the use of
forward-looking words such as “anticipate,” “believe,” “forecast,”
“estimate,” “expect,” and “intend,” among others. These
forward-looking statements are based on Tonix's current
expectations and actual results could differ materially. There are
a number of factors that could cause actual events to differ
materially from those indicated by such forward-looking statements.
These factors include, but are not limited to, risks related to
failure to obtain FDA clearances or approvals and noncompliance
with FDA regulations; delays and uncertainties caused by the global
COVID-19 pandemic; risks related to the timing and progress of
clinical development of our product candidates; our need for
additional financing; uncertainties of patent protection and
litigation; uncertainties of government or third party payor
reimbursement; limited research and development efforts and
dependence upon third parties; and substantial competition. As with
any pharmaceutical under development, there are significant risks
in the development, regulatory approval and commercialization of
new products. Tonix does not undertake an obligation to update or
revise any forward-looking statement. Investors should read the
risk factors set forth in the Annual Report on Form 10-K for the
year ended December 31, 2019, as filed with the Securities and
Exchange Commission (the “SEC”) on March 24, 2020, and periodic
reports filed with the SEC on or after the date thereof. All of
Tonix's forward-looking statements are expressly qualified by all
such risk factors and other cautionary statements. The information
set forth herein speaks only as of the date thereof.
Contacts
Jessica Morris (corporate)Tonix
Pharmaceuticalsinvestor.relations@tonixpharma.com(212) 688-9421
Olipriya Das (media)Russo
Partnersolipriya.das@russopartnersllc.com (646) 942-5588
Peter Vozzo
(investors)Westwickepeter.vozzo@westwicke.com (443) 213-0505
Tonix Pharmaceuticals (NASDAQ:TNXP)
Historical Stock Chart
From Mar 2024 to Apr 2024
Tonix Pharmaceuticals (NASDAQ:TNXP)
Historical Stock Chart
From Apr 2023 to Apr 2024